Alan Ashworth, PhD, FRS

E. Dixon Heise Distinguished Professor in Oncology, UCSF

President, UCSF Helen Diller Family Comprehensive Cancer Center; Senior Vice President for Cancer Services, UCSF Health; Professor of Medicine, Division of Hematology/Oncology, Department of Medicine, UCSF

Cancer Center Program Membership

Molecular Oncology

Research Summary

Alan Ashworth is President of the Helen Diller Family Comprehensive Cancer Center at University of California, San Francisco and Senior Vice President for clinical services, UCSF Health. Ashworth was a key member of the team that discovered the BRCA2 gene in 1995, which is linked to an increased risk of breast, ovarian and other cancers. In 2005, his lab described a way to exploit genetic weaknesses (using synthetic lethality) in cancer cells with mutated BRCA1 or BRCA2 genes, leading to a new approach to cancer treatment, PARP inhibition. Four different PARP inhibitors have now been approved by the FDA for the treatment of ovarian, breast, pancreatic and prostate cancer based on this observation, which was named by Nature in the top 20 discoveries in cancer in the 21st century. He continues to develop new treatments for cancer using genetic principles.

He has received a number of awards and prizes many of which recognize the innovative and translational nature of his work as well as its clinical impact. He is an elected member of the European Molecular Biology Organization (EMBO) and a Fellow of the Academy of Medical Sciences, the American Association of Arts and Sciences, the American Association of Cancer Research and the Royal Society. Prizes include the European Society of Medical Oncology (ESMO) Lifetime Achievement Award, the David T. Workman Memorial Award of the Samuel Waxman Cancer Research Foundation, the Meyenburg Foundation’s Cancer Research Award, the Genetics Society Medal, the Susan G Komen Brinker award and the inaugural Basser Global Prize.

Research Funding

  • September 1, 2018 - August 31, 2023 - DNA repair alterations in metastatic prostate cancer: functional and therapeutic implications , Principal Investigator . Sponsor: NIH, Sponsor Award ID: R01CA230516
  • August 5, 1999 - May 31, 2023 - Cancer Center Support Grant , Principal Investigator . Sponsor: NIH, Sponsor Award ID: P30CA082103

Education

1978 – 1981, BSc (Hons), Chemistry and Biochemistry, Imperial College of Science and Technology, University of London
1981 – 1984, PhD, Biochemistry, University College London
1986 – 1988, Postdoctoral Fellow, The Institute of Cancer Research
1984 – 1986, Postdoctoral Fellow, Department of Biochemistry, University College London

Honors & Awards

  • 2023
    ASCO 2023 Science of Oncology Award and Lecture
  • 2023
    Memorial Sloan Kettering Cancer Centerʻs C. Chester Stock Award Lectureship
  • 2020
    Emerson Collective Cancer Research Award
  • 2018
    Elected as Fellow, American Association for Cancer Research
  • 2018
    Pioneer Award, Precision Medicine World Conference
  • 2017
    Brinker Award for Scientific Distinction in Basic Science, Susan G. Komen
  • 2016
    Drexel Prize in Cancer Biology
  • 2016
    Appointed to American Association for Cancer Research Board of Directors
  • 2015
    Genetics Society Medal
  • 2015
    Spirit of Empowerment Award, Facing Our Risk of Cancer Empowered (FORCE)
  • 2013
    Basser Global Prize
  • 2012
    Scientist in Residence - University Duisberg-Essen/Essener Sparkasse
  • 2012
    Pathological Society of Great Britain and Ireland’s Goudie Medal
  • 2010
    AACR Distinguished Lectureship in Breast Cancer, San Antonio
  • 2010
    Meyenburg Foundation Cancer Research Award
  • 2010
    Samuel Waxman Cancer Research Foundation David Workman Memorial Award
  • 2009
    Elected Fellow of the European Academy of Cancer Sciences
  • 2009
    ESMO Lifetime Achievement Award
  • 2008
    Elected Fellow of the Royal Society
  • 2002
    Elected Fellow of the Academy of Medical Sciences
  • 1999
    Elected to EMBO
  • 1991
    British Postgraduate Medical Federation Prize

Selected Publications

  1. Nikkilä J, Kumar R, Campbell J, Brandsma I, Pemberton HN, Wallberg F, Nagy K, Scheer I, Vertessy BG, Serebrenik AA, Monni V, Harris RS, Pettitt SJ, Ashworth A, Lord CJ. Correction to: Elevated APOBEC3B expression drives a kataegic-like mutation signature and replication stress-related therapeutic vulnerabilities in p53-defective cells. Br J Cancer. 2026 Apr; 134(7):1111. View on PubMed
  2. Zhu X, Alvarez EA, Umetsu SE, Chapman JS, Chen LM, Ueda S, Henderson S, Nguyen P, Calabrese S, Russell J, Aguilar J, Smith SA, Shah N, Feeney L, Van Ziffle J, Turski ML, Ko AH, Munster PN, Ashworth A, Collisson EA, Aggarwal RR. Efficacy of the ATR inhibitor ceralasertib in patients with ARID1A-deficient gynecologic and other solid tumor malignancies. Clin Cancer Res. 2026 Feb 13. View on PubMed
  3. Herasymenko O, Silva M, Correy GJ, Abu-Saleh AAA, Ackloo S, Arrowsmith C, Ashworth A, Ban F, Beck H, Bishop KP, Bohórquez HJ, Bolotokova A, Breznik M, Chau I, Chen Y, Cherkasov A, Dehaen W, Della Corte D, Denzinger K, Doering NP, Edfeldt K, Edwards A, Fayne D, Gentile F, Gibson E, Gokdemir O, Gunnarsson A, Günther J, Irwin JJ, Jensen JH, Harding RJ, Hillisch A, Hoffer L, Hogner A, Hutchinson A, Kandwal S, Karlova A, Koirala K, Kotelnikov S, Kozakov D, Lee J, Lee S, Lessel U, Liu S, Liu X, Loppnau P, Meiler J, Moretti R, Moroz YS, Muvva C, Oprea TI, Paige B, Pandit A, Park K, Poda G, Protopopov MV, Pütter V, Ravichandran R, Rognan D, Rosta E, Sabnis Y, Scott T, Seitova A, Sharma P, Sindt F, Song M, Steinmann C, Stevens R, Talagayev V, Tararina VV, Tarkhanova O, Tingey D, Trant JF, Treleaven D, Tropsha A, Walters P, Wells J, Westermaier Y, Wolber G, Wortmann L, Zheng S, Fraser JS, Schapira M. CACHE Challenge #3: Targeting the Nsp3 Macrodomain of SARS-CoV-2. J Chem Inf Model. 2026 Feb 09; 66(3):1566-1581. View on PubMed
  4. Gou X, Chen H, Diolaiti ME, Ashworth A. Identification of a Two-Gene Biomarker Correlated with Sensitivity to Combined PARP7 Inhibition and AHR Activation in Cancer Cells. Cancer Res Commun. 2026 Jan 01; 6(1):5-16. View on PubMed
  5. Kim J, Correy GJ, Hall BW, Rachman MM, Mailhot O, Togo T, Gonciarz RL, Jaishankar P, Neitz RJ, Hantz ER, Doruk YU, Stevens MGV, Diolaiti ME, Reid R, Gopalkrishnan S, Krogan NJ, Renslo AR, Ashworth A, Shoichet BK, Fraser JS. Large scale prospective evaluation of co-folding across 557 Mac1-ligand complexes and three virtual screens. bioRxiv. 2025 Dec 29. View on PubMed
  6. Seo L, Farran I, Aslam A, Li X, Jaishankar P, Ashworth A, Fraser JS, Renslo AR, Wankowicz SA. Crystallographic Ensembles Reveal the Structural Basis of Binding Entropy in SARS-CoV2 Macrodomain. bioRxiv. 2025 Dec 23. View on PubMed
  7. Jaishankar P, Correy GJ, Matsui Y, Togo T, Rachman MM, Stevens MGV, Hantz ER, Zheng J, Diolaiti ME, Montano M, Taha TY, Rosecrans J, Pampel J, Krogan NJ, Shoichet BK, Ashworth A, Ott M, Fraser JS, Renslo AR. Discovery of AVI-6451, a Potent and Selective Inhibitor of the SARS-CoV-2 ADP-Ribosylhydrolase Mac1 with Oral Efficacy In Vivo. J Med Chem. 2026 Jan 08; 69(1):553-573. View on PubMed
  8. Suryawanshi RK, Jaishankar P, Correy GJ, Rachman MM, O'Leary PC, Taha TY, Matsui Y, Zapatero-Belinchón FJ, McCavitt-Malvido M, Doruk YU, Stevens MGV, Diolaiti ME, Jogalekar MP, Chen H, Richards AL, Kongpracha P, Bali S, Montano M, Rosecrans J, Matthay M, Togo T, Gonciarz RL, Gopalkrishnan S, Neitz RJ, Krogan NJ, Swaney DL, Shoichet BK, Ott M, Renslo AR, Ashworth A, Fraser JS. The Mac1 ADP-ribosylhydrolase is a therapeutic target for SARS-CoV-2. Elife. 2025 Nov 19; 14. View on PubMed
  9. Abrams RPM, Donahue RG, Ma J, Mao Y, Diolaiti ME, Ashworth A. An engineered cysteine sensor optimized for high-throughput screening identifies regulators of intracellular thiol levels. Cell Chem Biol. 2025 Nov 20; 32(11):1381-1396.e8. View on PubMed
  10. Jaishankar P, Correy GJ, Matsui Y, Togo T, Rachman MM, Stevens MGV, Hantz ER, Zheng J, Diolaiti ME, Montano M, Taha TY, Rosecrans J, Pampel J, Krogan NJ, Shoichet BK, Ashworth A, Ott M, Fraser JS, Renslo AR. Discovery of AVI-6451, a Potent and Selective Inhibitor of the SARS-CoV-2 ADP-Ribosylhydrolase Mac1 with Oral Efficacy in vivo. bioRxiv. 2025 Oct 14. View on PubMed
  11. Bardossy ES, Bergmann L, Henrion-Lacritick A, Nigg J, Correy GJ, Ashworth A, Fraser JS, Saleh MC. Macrodomain ADP-ribose binding but not ADP-ribosylhydrolase activity is critical for chikungunya virus infection of Aedes mosquitoes. bioRxiv. 2025 Oct 09. View on PubMed
  12. Blaisdell A, Bachl S, Sandoval LR, Ching C, Bowman CJ, Kale N, Prabandham M, Diolaiti M, Havig C, Advincula R, Lenci N, Li Z, Yamashita E, Wang CH, Zhang S, Liu Q, Achacoso P, Stibor D, Øynebråten I, Seo J, Ashworth A, Marson A, Ye CJ, Malynn BA, Eyquem J, Carnevale J, Ma A. Base-editing a single missense mutation in A20 enhances CAR-T cell efficacy. bioRxiv. 2025 Oct 06. View on PubMed
  13. Suryawanshi RK, Jaishankar P, Correy GJ, Rachman MM, O'Leary PC, Taha TY, Matsui Y, Zapatero-Belinchón FJ, McCavitt-Malvido M, Doruk YU, Stevens MGV, Diolaiti ME, Jogalekar MP, Chen H, Richards AL, Kongpracha P, Bali S, Montano M, Rosecrans J, Matthay M, Togo T, Gonciarz RL, Gopalkrishnan S, Neitz RJ, Krogan NJ, Swaney DL, Shoichet BK, Ott M, Renslo AR, Ashworth A, Fraser JS. The Mac1 ADP-ribosylhydrolase is a Therapeutic Target for SARS-CoV-2. bioRxiv. 2025 Oct 06. View on PubMed
  14. Salami A, Adiele U, Coate G, Diolaiti M, Chen H, Lu J, Ashworth A, Patil M, Fleishman JS, Ramaraju A, Patel A, Patel H, Patel K, Murakami M, Ambudkar SV, Talele TT. Structure-activity relationship studies on 2-thienylidene substituted 3-oxo-2,3-dihydrobenzofuran-7-carboxamides as poly (ADP-ribose) polymerase inhibitors. Bioorg Chem. 2025 Oct; 165:108941. View on PubMed
  15. Bedia JS, Delgado-Gonzalez A, Huang YW, Gonzalez VD, Funingana IG, Rahil Z, Mike A, Lowber A, Vias M, Ashworth A, Brenton JD, Fantl WJ. Coordinated protein modules define DNA damage responses to carboplatin at single-cell resolution in human ovarian carcinoma models. Cell Rep Med. 2025 Sep 16; 6(9):102295. View on PubMed
  16. Chen DF, Roe LT, Yuping L, Borges AL, Zhang JY, Babbar P, Maji S, Stevens MGV, Correy GJ, Diolaiti ME, Smith DH, Ashworth A, Stroud RM, Kelly MJS, Bondy-Denomy J, Fraser JS. AcrIF11 is a potent CRISPR-specific ADP-ribosyltransferase encoded by phage and plasmid. mBio. 2025 Sep 10; 16(9):e0169825. View on PubMed
  17. Woods B, Kearns B, Schmitt L, Jankovic D, Rothery C, Harnan S, Hamilton J, Scope A, Ren S, Bojke L, Wilcox M, Hope W, Leonard C, Howard P, Jenkins D, Ashworth A, Bentley A, Sculpher M. Correction: Assessing the Value of New Antimicrobials: Evaluations of Cefiderocol and Ceftazidime-Avibactam to Inform Delinked Payments by the NHS in England. Appl Health Econ Health Policy. 2025 Jul; 23(4):753-754. View on PubMed
  18. Chen DF, Roe LT, Li Y, Borges AL, Zhang JY, Babbar P, Maji S, Stevens MGV, Correy GJ, Diolaiti ME, Smith DH, Ashworth A, Stroud RM, Kelly MJS, Bondy-Denomy J, Fraser JS. AcrIF11 is a potent CRISPR-specific ADP-ribosyltransferase encoded by phage and plasmid. bioRxiv. 2025 Jun 02. View on PubMed
  19. Correy GJ, Rachman MM, Togo T, Gahbauer S, Doruk YU, Stevens MGV, Jaishankar P, Kelley B, Goldman B, Schmidt M, Kramer T, Radchenko DS, Moroz YS, Ashworth A, Riley P, Shoichet BK, Renslo AR, Walters WP, Fraser JS. Exploration of structure-activity relationships for the SARS-CoV-2 macrodomain from shape-based fragment linking and active learning. Sci Adv. 2025 May 30; 11(22):eads7187. View on PubMed
  20. Li H, Younger NS, Malik B, Shin HJ, Zhang C, Niknafs Y, Zhao SG, Wilder-Romans K, Pitchiaya S, Han S, Barnard T, Lloyd P, Zhang M, Chesner LN, Calvert M, Egusa EA, Zhu J, Chou J, Das R, Kothari V, Shenoy T, Diolaiti ME, Malik R, Prensner JR, Burlingame A, Ashworth A, Chinnaiyan AM, Feng F, Li H. Identification and Characterization of PLUTO-201, a Novel Long Non-Coding RNA Associated with Poor Outcomes in Prostate Cancer. bioRxiv. 2025 May 24. View on PubMed

Go to UCSF Profiles, powered by CTSI